Patents by Inventor Chrishan Samuel

Chrishan Samuel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating allergic airways disease (AAD)/asthma
    Patent number: 11471493
    Abstract: The invention relates to use of a mesenchymoangioblast-derived mesenchymal stem cell (MSC-MSC) for treating allergic airway disease (AAD)/asthma in a subject.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: October 18, 2022
    Assignee: CYNATA THERAPEUTICS LIMITED
    Inventors: Chrishan Samuel, Simon Royce
  • METHOD FOR TREATING ALLERGIC AIRWAYS DISEASE (AAD)/ASTHMA
    Publication number: 20200276243
    Abstract: The invention relates to use of a mesenchymoangioblast-derived mesenchymal stem cell (MSC-MSC) for treating allergic airway disease (AAD)/asthma in a subject.
    Type: Application
    Filed: August 31, 2018
    Publication date: September 3, 2020
    Applicant: CYNATA THERAPEUTICS LIMITED
    Inventors: CHRISHAN SAMUEL, SIMON ROYCE
  • METHODS OF MODULATING APOPTOSIS BY ADMINISTRATION OF RELAXIN AGONISTS OR ANTAGONISTS
    Publication number: 20080085275
    Abstract: The present invention relates to the discovery that relaxin is associated with the development or maturation of body tissues. Knockouts of the gene encoding relaxin result in various abnormalities in the development of various tissues. The present invention provides methods of modulating apoptosis by administering a relaxin agonist or antagonist to a subject.
    Type: Application
    Filed: July 23, 2007
    Publication date: April 10, 2008
    Applicant: Molecular Medicine Research Institute
    Inventors: Edward Amento, Chrishan Samuel
  • Prevention of fibrosis following cardiac injury
    Publication number: 20060264367
    Abstract: A method for treating cardiac fibrosis resulting from injury of a mammalian heart is described comprising the step of contacting a therapeutically effective amount of relaxin and/or an LGR7 activating agent with cardiac cells following the injury in an amount sufficient to reduce the fibrosis. Also described are methods for protecting the heart following an ischemic event, inhibiting the proliferation of activated fibroblasts and antagonising collagen secretion or deposition in a mammalian heart.
    Type: Application
    Filed: May 21, 2005
    Publication date: November 23, 2006
    Applicants: Howard Florey Institute, Baker Medical Research Institute
    Inventors: Chrishan Samuel, Ross Alexander Bathgate, Geoffrey Tregear, Xiao-Jun Du
  • Methods of modulating apoptosis by administration of relaxin agonists or antagonists
    Publication number: 20050032683
    Abstract: The present invention relates to the discovery that relaxin is associated with the development or maturation of body tissues. Knockouts of the gene encoding relaxin result in various abnormalities in the development of various tissues. The present invention provides methods of modulating apoptosis by administering a relaxin agonist or antagonist to a subject.
    Type: Application
    Filed: October 4, 2001
    Publication date: February 10, 2005
    Inventors: Edward Amento, Chrishan Samuel
  • Human 3 relaxin
    Publication number: 20050026822
    Abstract: Human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues having a modified A chain and/or a modified B chain are described. Also described are nucleic acid sequences encoded human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues. Also described are methods for the treatment of conditions responsive to administration of H3 relaxin or analogues thereof.
    Type: Application
    Filed: October 2, 2002
    Publication date: February 3, 2005
    Applicant: AstraZeneca AB
    Inventors: Geoffrey Tregear, Ross Alexander Bathgate, Chrishan Samuel, Tanya Burazin, Andrew Gundlach, John Wade